Stockreport

Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre

Acasti Pharma, Inc.  (ACST) 
Last acasti pharma, inc. earnings: 2/14 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: acastipharma.com/investors
PDF Reports 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively, as well as 42.2% reduct [Read more]